Top Markets
#1 EXOD EXOD +22.08%
#2 Status Status +18.25%
#3 Ontology Gas Ontology Gas +14.98%
#4 Derive Derive +11.23%
#5 Fake World Assets Fake World Assets +9.05%
#6 aelf aelf +8.29%
#7 Anvil Anvil +5.72%
#8 Tornado Cash Tornado Cash +5.44%
#9 The Black Bull The Black Bull +5.21%
#10 B3 (Base) B3 (Base) +5.04%
Coin of the day
EXOD EXOD
設定
言語
日本
通貨
USD
テーマ
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc.

VICP
株式のランク #25708
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive... Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
株価
$1.45
最終同期: 2026-08-19
時価総額
$46.94M
変化（1日）
0.00%
変化（1年）
-18.08%
国
US
取引 Vicapsys Life Sciences, Inc. (VICP)

カテゴリー

Healthcare
Vicapsys Life Sciences, Inc.（VICP）の収益
Aug 2026 時点の収益 TTM: 0
Vicapsys Life Sciences, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Vicapsys Life Sciences, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US